Cam Gallagher
Chairman
Opus Genetics, Inc. (IRD)Board Member
Opus Genetics, Inc. (IRD)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Cam Gallagher
Cam Gallagher is recorded as Chairman and Board Member at Opus Genetics, Inc. (IRD) and CFO at Zentalis Pharmaceuticals, Inc. (ZNTL). Zentalis Pharmaceuticals, Inc. reported in an 8-K filed November 13, 2024 that Cam Gallagher resigned as member of the Board, effective November 13, 2024. Zentalis Pharmaceuticals, Inc. reported in an 8-K filed November 13, 2024 that Cam Gallagher resigned as President, effective November 13, 2024. Zentalis Pharmaceuticals, Inc. reported in an 8-K filed November 13, 2024 that Cam Gallagher resigned as Interim Chief Financial Officer, effective November 13, 2024. Equibles holds 4 filed executive changes naming Cam Gallagher; each is listed under recent activity with its source filing. The proxy statement of Zentalis Pharmaceuticals, Inc. reports total compensation of $5,819,024 for Cam Gallagher in fiscal 2024, including a base salary of $537,199. Disclosed compensation is on record for 3 fiscal years.
“On November 12, 2024, Cam Gallagher resigned as President, Interim Chief Financial Officer, a member of the Board, and from all other positions held with the Company and its affiliates, effective on the Transition Date.”
“On November 12, 2024, Cam Gallagher resigned as President, Interim Chief Financial Officer, a member of the Board, and from all other positions held with the Company and its affiliates, effective on the Transition Date.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2024-04-05–present
-
Current
Start not stated–present
-
Current
Start not stated–present
-
2014-01-01–2024-11-13
-
Start not stated–2025-04-30
Last confirmed by a filing; no departure on record
-
Start not stated–2024-11-13
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Opus Genetics, Inc.
Other people whose current roles at this company are on record from its filings.
- Dr. George Magrath CEO, Board Member
- George Magrath CEO, Board Member
- George Magrath, M.D., M.B.A., M.S. CEO, Board Member
- Richard Rodgers CEO, Board Member
- Nirav Jhaveri CFO
- Rob Gagnon CFO
- Robert Gagnon CFO, Chief Accounting Officer
- Joseph K. Schachle COO
- Joseph Schachle COO
- Amy Rabourn Chief Accounting Officer
Leadership on record at Zentalis Pharmaceuticals, Inc.
Other people whose current roles at this company are on record from its filings.
- Julie Eastland CEO, Board Member
- Kimberly Blackwell, M.D. CEO
- David M. Johnson Chairman
- Scott Myers Chairman, Board Member
- Vincent Vultaggio CFO, Chief Accounting Officer
- Iris Roth COO
- Iris Roth, Ph.D. COO
- James B. Bucher General Counsel
- David Johnson Board Member
- Enoch Kariuki Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Former President, Interim Chief Financial Officer and Interim Treasurer | $537,199 | $5,819,024 |
| 2023 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Former President, Interim Chief Financial Officer and Interim Treasurer | $593,600 | $8,581,060 |
| 2022 | Zentalis Pharmaceuticals, Inc. (ZNTL) | President, Interim Chief Financial Officer and Interim Treasurer | $485,942 | $10,629,545 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.